NCT01532011View on ClinicalTrials.gov

Erlotinib in Combination With Pralatrexate in Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Advanced CancersSolid Tumors
Interventions
DRUG

Erlotinib

"Dose escalation group starting dose: 75 mg by mouth daily for a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."

DRUG

Pralatrexate

"Dose escalation group starting dose: 15 mg/m2 by vein on days 1, 8, and 15 of a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01532011 - Erlotinib in Combination With Pralatrexate in Advanced Malignancies | Biotech Hunter | Biotech Hunter